Ebola virus disease (EVD), also known as Ebola haemorrhagic fever in humans and other primates, is a serious, frequently fatal sickness. Ebola Virus Disease (EVD) is a devastating disease that affects both humans and nonhuman primates. After becoming infected with the virus, symptoms often appear two to three weeks later. Fever, sore throat, muscle soreness, and headaches are generally the first signs. Vomiting, diarrhoea, dermatitis, and reduced liver and renal function are common side effects, and some people bleed internally and externally as a result. The disease kills between 25% and 90% of people affected, with an average death rate of 50%. The most common cause of death is shock from fluid loss, which happens six to 16 days after the first symptoms show. Direct contact with infected body fluids, such as blood from infected humans or other animals, or contact with items that have recently been contaminated with infected body fluids, is how the virus spreads.
Zika virus disease is caused by a virus that is mostly transmitted by Aedes mosquitoes that bite during the day. Fever, rash, conjunctivitis, muscle and joint discomfort, malaise, and headache are all common symptoms. The symptoms usually persist 2–7 days. The majority of those infected with the Zika virus do not experience any symptoms. In Africa, the Americas, Asia, and the Pacific, Zika virus outbreaks have been reported.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain